Granules India shares climb nearly 7% on USFDA nod for drug
The scrip advanced by 6.61% to end at Rs103.15 on BSE. Intra-day, it zoomed 10.18% to Rs106.60. On NSE, shares of the company surged 6.67% to close at Rs103.15
New Delhi:Shares of drug firm Granules India Thursday soared nearly 7% after the company’s subsidiary received approval from the US health regulator for Methylergonovine tablets, used for prevention and control of postpartum haemorrhage.
The scrip advanced by 6.61% to end at Rs103.15 on BSE. Intra-day, it zoomed 10.18% to Rs106.60. On NSE, shares of the company surged 6.67% to close at Rs103.15.
On the equity volume front, 8.75 lakh shares of the company were traded on BSE and over one crore shares changed hands on NSE during the day.
In a filing to the BSE, Granules India said, “the US Food and Drug Administration (US FDA) has approved its abbreviated new drug applications (ANDA) for Methylergonovine 0.2 mg tablets.
The ANDA was filed by Granules Pharmaceuticals Inc, a wholly owned subsidiary of Granules India Ltd”.
- States, PSUs invited to bid for Air India building at Nariman Point
- HDFC Bank Q3 net profit rises 20% to Rs 5,586 crore
- FedEx starts $575 million worker buyout as overseas demand cools
- Facebook faces potential record US fine on privacy violations: Report
- India’s data must be controlled by Indians, not by global corporates: Mukesh Ambani on data colonisation
Editor's Picks »
- What to expect from Q3 results of IndiGo, SpiceJet, Jet Airways
- Forget privatisation, govt has hugged its banks tighter
- Flat profit, rising debt are growing worries for Reliance
- Q3 results: HUL growth off a high base shows it’s on a roll
- DCB Bank Q3 results: Small loans give big pain as farm, mortgages lift delinquencies